Stay updated on AAV2/6 Gene Therapy SB-525 in Severe Hemophilia A Clinical Trial
Sign up to get notified when there's something new on the AAV2/6 Gene Therapy SB-525 in Severe Hemophilia A Clinical Trial page.

Latest updates to the AAV2/6 Gene Therapy SB-525 in Severe Hemophilia A Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoChange DetectedThe page now includes a new section with helpful links provided by Pfizer for obtaining contact information for nearby study centers.SummaryDifference1.0%
- Check23 days agoChange DetectedThe webpage has been updated to include new information about the SB-525 study, specifically regarding dose selection based on safety and kinetics of FVIII levels, and it has been revised to version 2.15.0. Notably, significant details about the study's purpose and methodology have been removed.SummaryDifference23%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe webpage has removed important information regarding service performance issues and contact details for assistance, which may impact user experience.SummaryDifference3%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference2%
Stay in the know with updates to AAV2/6 Gene Therapy SB-525 in Severe Hemophilia A Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AAV2/6 Gene Therapy SB-525 in Severe Hemophilia A Clinical Trial page.